Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1982 1
1987 1
1988 3
1989 7
1991 3
1992 6
1993 3
1994 8
1995 13
1996 3
1997 9
1998 10
1999 10
2000 7
2001 8
2002 11
2003 10
2004 11
2005 11
2006 6
2007 9
2008 11
2009 16
2010 9
2011 13
2012 12
2013 4
2014 8
2015 11
2016 11
2017 16
2018 8
2019 12
2020 15
2021 10
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

271 results
Results by year
Filters applied: . Clear all
Page 1
Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Lu X, et al. Among authors: troncoso p. Nature. 2017 Mar 30;543(7647):728-732. doi: 10.1038/nature21676. Epub 2017 Mar 20. Nature. 2017. PMID: 28321130 Free PMC article.
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Corn PG, et al. Among authors: troncoso p. Lancet Oncol. 2019 Oct;20(10):1432-1443. doi: 10.1016/S1470-2045(19)30408-5. Epub 2019 Sep 9. Lancet Oncol. 2019. PMID: 31515154 Free PMC article. Clinical Trial.
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.
Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ, Patel NB, Guo Z, Ramamoorthy V, Tieu TN, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin EJ, Yao W, Pan X, Ding Z, Shi Y, Li L, Chang Q, Troncoso P, Logothetis CJ, McArthur MJ, Chin L, Wang YA, DePinho RA. Wang G, et al. Among authors: troncoso p. Cancer Discov. 2016 Jan;6(1):80-95. doi: 10.1158/2159-8290.CD-15-0224. Epub 2015 Dec 23. Cancer Discov. 2016. PMID: 26701088 Free PMC article.
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA. Zhao D, et al. Among authors: troncoso p. Nature. 2017 Feb 23;542(7642):484-488. doi: 10.1038/nature21357. Epub 2017 Feb 6. Nature. 2017. PMID: 28166537 Free PMC article.
Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Aparicio AM, et al. Among authors: troncoso p. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6. Clin Cancer Res. 2013. PMID: 23649003 Free PMC article.
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC. Liu B, et al. Among authors: troncoso p. Clin Cancer Res. 2019 Nov 15;25(22):6839-6851. doi: 10.1158/1078-0432.CCR-19-0317. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439587 Free PMC article.
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. Gao J, et al. Among authors: troncoso p. Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27. Nat Med. 2017. PMID: 28346412 Free PMC article.
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Li L, et al. Among authors: troncoso p. Sci Signal. 2017 May 23;10(480):eaam7479. doi: 10.1126/scisignal.aam7479. Sci Signal. 2017. PMID: 28536297 Free PMC article.
Detection and Treatment of Primary Prostatic Melanoma.
Li R, Zhang M, Duplisea JJ, Troncoso P, Ward JF. Li R, et al. Among authors: troncoso p. Urology. 2019 Jan;123:16-19. doi: 10.1016/j.urology.2018.08.035. Epub 2018 Sep 5. Urology. 2019. PMID: 30195014 Review.
271 results